Early detection AltPep focuses on early disease-modifying treatments and detection tools for amyloid diseases, creating sales opportunities in preclinical and early-stage diagnostics markets targeting Alzheimer’s disease and related conditions.

SOBIN-AD edge Lead program SOBIN-AD shows promise in neutralizing soluble oligomers and enhancing clearance of toxic Aβ species, offering a clear value proposition for partnerships or licensing discussions with pharma companies pursuing disease-modifying Alzheimer’s therapies.

Clinical readiness Active preclinical data presentation at major conferences (AAIC, CTAD) indicates ongoing validation and market momentum, suggesting readiness for collaboration, pilot studies, or co-development initiatives.

Strategic leadership Recent board and business roles, plus advisory enhancements, signal strong governance and strategic execution potential for investors or industry partners seeking experienced biotechnology collaborators.

Financial foothold With a funding base of around $76M and mid-range revenue, AltPep demonstrates financial viability to support business development efforts, joint ventures, and pilot programs with potential licensing or milestone-based arrangements.